Biomarkers for renal cell tumours].

Philip Zeuschner, Angela Zaccagnino, Kerstin Junker

Aktuelle Urologie 2021 Sep

filter terms:

During the last three decades, renal tumours have become increasingly well differentiated on the basis of their histopathological and molecular features. This subtyping has increasingly impacted clinical practice because more therapeutic options are available in organ-confined and metastatic renal cell tumours. The knowledge of the underlying molecular alterations is essential to develop molecular targeted therapies and to select the most effective systemic therapy for each patient. This manuscript gives an overview of the molecular differentiation on the one hand, and on diagnostic, prognostic and predictive biomarkers on the other hand. Thieme. All rights reserved.